文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

组胺-2受体拮抗剂与质子泵抑制剂在脓毒性休克患者应激性溃疡预防中的比较

Comparison of Histamine-2 Receptor Antagonists and Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Patients With Septic Shock.
PubMed 文献 · Crit Care Med · 2025-12-17
一句话结论在脓毒性休克成人中,质子泵抑制剂较组胺-2受体拮抗剂与住院期间上消化道出血发生率更低相关(OR 0.78),死亡率等无显著差异。

这项回顾性、多中心、倾向加权队列研究纳入美国220家医院中住院当天起始H2RA或PPI的成人脓毒性休克患者共15,102例(H2RA 5,492例,PPI 9,610例)。采用逆概率治疗加权调整混杂后,PPI组上消化道出血发生率显著低于H2RA组(OR 0.78,95%CI 0.64-0.96,p=0.016),法莫替丁与泮托拉唑的敏感性分析结果一致(OR 0.80,95%CI 0.65-0.97,p=0.025)。住院死亡率、呼吸机相关性肺炎、艰难梭菌感染及住院时间均无显著差异。

要点

  • 脓毒性休克成人住院当天起始PPI较H2RA与上消化道出血发生率更低相关(OR 0.78,95%CI 0.64-0.96,p=0.016)。
  • 法莫替丁与泮托拉唑比较的敏感性分析支持上述结果(OR 0.80,95%CI 0.65-0.97,p=0.025)。
  • 住院死亡率(OR 0.98,95%CI 0.91-1.06)、呼吸机相关性肺炎(OR 0.93,95%CI 0.83-1.04)、艰难梭菌感染(OR 1.32,95%CI 0.82-2.13)及住院时间(IRR 1.01,95%CI 0.98-1.05)均无显著差异。
  • 研究纳入15,102例患者,其中5,492例使用H2RA、9,610例使用PPI,58.1%住院期间接受有创机械通气。

适用人群与场景

  • 美国220家社区及教学医院中年龄≥18岁的成人脓毒性休克患者,于住院当天起始H2RA或PPI。

处置流程与药物剂量

  • H2RA组使用法莫替丁;PPI组使用泮托拉唑、奥美拉唑、埃索美拉唑或兰索拉唑。

研究设计与关键结果

  • 回顾性、多中心、倾向加权队列研究,纳入15,102例患者(H2RA 5,492例,PPI 9,610例),平均年龄65.8±14.9岁,女性47.8%,58.1%住院期间接受有创机械通气。
  • 主要终点住院期间上消化道出血:经逆概率治疗加权调整后,PPI组较H2RA组发生率更低(OR 0.78,95%CI 0.64-0.96,p=0.016)。
  • 敏感性分析法莫替丁与泮托拉唑比较:OR 0.80,95%CI 0.65-0.97,p=0.025。
  • 住院死亡率:OR 0.98,95%CI 0.91-1.06,p=0.691,无显著差异。
  • 呼吸机相关性肺炎:OR 0.93,95%CI 0.83-1.04,p=0.188,无显著差异。
  • 艰难梭菌感染:OR 1.32,95%CI 0.82-2.13,p=0.246,无显著差异。
  • 住院时间:发生率比1.01,95%CI 0.98-1.05,p=0.417,无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性、多中心、倾向加权队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒性休克成人中,住院当天起始PPI较H2RA与住院期间上消化道出血发生率更低相关,死亡率、呼吸机相关性肺炎、艰难梭菌感染及住院时间无显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To compare the effectiveness of histamine-2 receptor antagonists (H2RAs) vs. proton pump inhibitors (PPIs) for stress ulcer prophylaxis on the occurrence of upper gastrointestinal bleeding (UGIB) and other clinical outcomes in hospitalized patients with septic shock.

DESIGN: Retrospective, multicenter, propensity-weighted cohort study.

SETTING: Conducted across 220 geographically diverse community and teaching hospitals in the United States.

PATIENTS: Adult patients (age ≥ 18 yr) with septic shock who were initiated on either H2RAs or PPIs on the day of hospital admission.

INTERVENTIONS: H2RAs (famotidine) or PPIs (pantoprazole, omeprazole, esomeprazole, or lansoprazole).

MEASUREMENTS AND MAIN RESULTS: The primary outcome was the occurrence of UGIB during hospitalization. Secondary outcomes included in-hospital mortality, ventilator-associated pneumonia, Clostridioides difficile infection, and hospital length of stay. Propensity scores with inverse probability of treatment weighting (IPTW) were used to control for confounding. Among 15,102 patients (5,492 H2RA, 9,610 PPI), the mean age was 65.8 ± 14.9 years, 47.8% were female, and 58.1% received invasive mechanical ventilation during hospitalization. After IPTW adjustment, PPI use was associated with a lower occurrence of UGIB compared with H2RA (odds ratio [OR], 0.78; 95% CI, 0.64-0.96; p = 0.016). A sensitivity analysis comparing famotidine to pantoprazole confirmed this finding (OR, 0.80; 95% CI, 0.65-0.97; p = 0.025). No significant differences were observed in in-hospital mortality (OR, 0.98; 95% CI, 0.91-1.06; p = 0.691), ventilator-associated pneumonia (OR, 0.93; 95% CI, 0.83-1.04; p = 0.188), C. difficile infection (OR, 1.32; 95% CI, 0.82-2.13; p = 0.246), or hospital length of stay (incidence rate ratio, 1.01; 95% CI, 0.98-1.05; p = 0.417).

CONCLUSIONS: In this large, diverse cohort of U.S. hospitalized adults with septic shock, PPI use for stress ulcer prophylaxis was associated with a significantly lower occurrence of UGIB compared with H2RA, with no significant differences in mortality, ventilator-associated pneumonia, C. difficile infection, or hospital length of stay.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Patanwala AE, Erstad BL. Comparison of Histamine-2 Receptor Antagonists and Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Patients With Septic Shock. Crit Care Med. 2025. PMID: 41405382. doi:10.1097/CCM.0000000000006996

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。